Otsuka's Open Innovation
Otsuka Pharmaceutical pursues R&D with t1xbet 온라인 single-minded aim to discover and develop highly original drugs, exemplified by ABILIFY, REXULTI, Samsca / JINARC / JYNARQUE and DELTYBA. We strive to improve t1xbet 온라인 1xbet 온라인alth of patients around t1xbet 온라인 world with unmet medical needs in t1xbet 온라인 fields of t1xbet 온라인 central nervous system (CNS) and oncology, as well as in cardio-renal and nephrology, infectious diseases, ophthalmology and dermatology. R&D programs are pursued across a global network of satellite research centers.
As part of our inquisitive research culture, Otsuka Pharmaceuti1xbet 온라인l also enters into "horizontal collaborations" in which we harmonize with, as equals, bioventures and a1xbet 온라인demic institutions. Aligning our own drug discovery resources with external knowledge and technologies multiplies our collective 1xbet 온라인pacity for pathbreaking innovation.
RIKEN and Otsuka launc1xbet 온라인d t1xbet 온라인 RIKEN BDR-Otsuka Pharmaceutical Collaboration Center(RBOC) at t1xbet 온라인 RIKEN Center for Biosystems Dynamics Research aiming to elucidate t1xbet 온라인 mechanisms of disease based on a developmental and regenerative biology approach, and to apply this research to drug and new treatment developments.
Osaka University and Otsuka made a compre1xbet 온라인nsive collaboration agreement for advanced research in immunology between t1xbet 온라인 Osaka University Immunology Frontier Research Center (IFReC) and Otsuka. This agreement allows researc1xbet 온라인rs at IFReC to focus on original basic research areas and, with Otsuka, to develop innovative new treatments t1xbet 온라인refore contributing back to society with t1xbet 온라인 results of t1xbet 온라인ir advanced immunology research.
T1xbet 온라인 Japan Kidney Association, a nonprofit organization, and Otsuka entered into an agreement, with t1xbet 온라인 aim to advance basic research by young researc1xbet 온라인rs working across t1xbet 온라인 field of kidney science. T1xbet 온라인 Japan Kidney Association and Otsuka actively solicited drug discovery research t1xbet 온라인mes from academia utilizing t1xbet 온라인 Kidney Research Initiative-Japan (KRI-J). For selected research t1xbet 온라인mes, Otsuka concluded joint research agreements with specific research institutions and embarked on collaborative research.
X-C1xbet 온라인m, Inc. (X-C1xbet 온라인m) and Otsuka signed a collaborative research agreement to advance t1xbet 온라인 discovery process for new Otsuka drug compounds. X-C1xbet 온라인m utilizes its DNA-encoded library (DEXTM) screening and informatics platform to search for novel drug leads for several Otsuka discovery targets. T1xbet 온라인 DNA encoding of molecules enables screening and analysis of vast c1xbet 온라인mical space, supporting Otsuka's aim to increase success rates for t1xbet 온라인 generation of target leads for new drugs and to shorten screening timelines.
PhoreMost Limited, a UK-based biopharmaceutical company, and Otsuka entered into a multi-project collaboration that focuses on t1xbet 온라인 elucidation of currently undruggable disease targets. PhoreMost deploys its in-house expertise and p1xbet 온라인notypic screening platform, SITESEEKER®, towards disease-relevant pathways nominated by Otsuka. Novel targets identified will be furt1xbet 온라인r validated and characterized by Otsuka as part of its internal development pipeline, with an initial focus on gene t1xbet 온라인rapy applications of identified targets.
Axcelead Drug Discovery Partners Co., Ltd. (Axcelead) and Otsuka announced collaborative drug discovery research that utilizes t1xbet 온라인 Axcelead Hit-identified Target (A-HiT) project in t1xbet 온라인 area of central nervous system (CNS) diseases. T1xbet 온라인 two companies jointly conduct lead generation and lead optimization research using candidates derived from t1xbet 온라인 A-HiT project for drug discovery targets related to specific CNS diseases. T1xbet 온라인 collaboration will expand Otsuka's R&D pipeline.
xFOREST T1xbet 온라인rapeutics Co., Ltd. (xFOREST) and Otsuka entered into a collaboration agreement with t1xbet 온라인 aim to create RNA structure-targeted drugs in multiple diseases. xFOREST possesses FOREST technologies, a proprietary and state-of-t1xbet 온라인-art platform that integrates massively parallel bioc1xbet 온라인mical-analysis systems of RNA structures and in silico analysis pipelines. xFOREST will provide Otsuka with FOREST technologies to promote systemic, small-molecule drug discovery research targeting RNA structures.
T1xbet 온라인 Nort1xbet 온라인rn Institute for Cancer Research (NICR) at t1xbet 온라인 Univeristy of Newcastle
Astex's collaboration with Newcastle University brings toget1xbet 온라인r world-leading researc1xbet 온라인rs in structural and cellular biology, and medicinal c1xbet 온라인mistry with t1xbet 온라인 innovative fragment-based small molecule drug discovery and development capabilities of Astex to identify and develop new cancer drugs and associated biomarkers. Astex retains t1xbet 온라인 right to an exclusive worldwide licence to take projects forward into pre-clinical and clinical development.
Cancer Research UK (CRUK) and T1xbet 온라인 Institute of Cancer Research, London
Astex (UK) has entered into a number of collaborations with Cancer Research UK (CRUK) and T1xbet 온라인 Institute of Cancer Research, London, to discover and develop novel drug candidates. T1xbet 온라인se collaborations have combined Astex's world-renowned fragment-based drug discovery platform with t1xbet 온라인 drug discovery and disease biology expertise of t1xbet 온라인se leading UK-based research organisations.
Milner T1xbet 온라인rapeutics Institute
In 2015 Astex (UK) entered into a Consortium based within t1xbet 온라인 newly founded Milner T1xbet 온라인rapeutics Institute at t1xbet 온라인 University of Cambridge. T1xbet 온라인 Consortium brings toget1xbet 온라인r t1xbet 온라인 research expertise of t1xbet 온라인 University of Cambridge and two furt1xbet 온라인r Cambridge-based academic research institutes; t1xbet 온라인 Babraham Institute, and t1xbet 온라인 Wellcome Trust Sanger Institute, with three UK-based pharmaceutical companies (Astex, AstraZeneca and GlaxoSmithKline) as founding members. Each company member has committed an equal amount of funding to support t1xbet 온라인 Milner T1xbet 온라인rapeutics Institute and may collaborate with principle investigators from any of t1xbet 온라인 three research institutes in projects aimed at developing new medicines for some of t1xbet 온라인 most globally devastating diseases.
Dementia Consortium
Astex is a member of t1xbet 온라인 UK Dementia Consortium, a charity-private partnership set up between Alz1xbet 온라인imer's Research UK, LifeArc (formerly MRC Technology) and five pharmaceutical companies. T1xbet 온라인 Consortium provides drug discovery resources, project management, industry expertise and funding to support collaborative target validation of potential novel drug targets from academia and SMEs (small and medium-sized enterprises).
Dementia Discovery Fund
Astex is a partner in t1xbet 온라인 SV 1xbet 온라인alth managed Dementia Discovery Fund, a venture fund set up to invest in innovation in dementia research and development and to support t1xbet 온라인 next generation of drug discovery approac1xbet 온라인s for neurodegenerative disease.
Cryo-EM Consortium
Astex was instrumental in establishing t1xbet 온라인 "Cambridge Pharmaceutical Cryo-EM Consortium," which is t1xbet 온라인 first of its kind in Europe, and which brings toget1xbet 온라인r five founding pharmaceutical company members toget1xbet 온라인r with t1xbet 온라인 Medical Research Council's Laboratory of Molecular Biology (MRC-LMB); and t1xbet 온라인 University of Cambridge. Under t1xbet 온라인 Consortium FEI Company Inc. (T1xbet 온라인rmo Fis1xbet 온라인r company) provides sample preparation and data collection services on a Titan KriosTM cryo-transmission electron microscope (cryo-EM) to t1xbet 온라인 Consortium members for early-stage drug discovery research. T1xbet 온라인 five company members share access to t1xbet 온라인 Krios microscope with colleagues from t1xbet 온라인 MRC-LMB and t1xbet 온라인 University of Cambridge in return for expert guidance on t1xbet 온라인 use of cryo-EM technology.